Breast Cancer Coverage from Every Angle


Vedotin Antibody-Drug Conjugate: Focus of First-in-Human Study in Advanced Solid Tumors
Are Younger Women in Canada Experiencing Diagnostic Delays in Breast Cancer?
Final Phase III Trial Results of Trastuzumab Duocarmazine in Metastatic Breast Cancer
Do All Subtypes of Triple-Negative Breast Cancer Respond to Atezolizumab?
AKT Inhibitor Plus Hormone Therapy Approved by the FDA for Breast Cancer
Race and Neighborhood Deprivation: Predictors of Survival in Breast Cancer?
FALCON Trial: Fulvestrant vs Anastrozole in Hormone Receptor–Positive Advanced Breast Cancer
BRCA Testing in Patients With Breast Cancer: Does Type of Insurance Matter?
Update on Use of Dato-DXd Plus Durvalumab in Triple-Negative Breast Cancer
ASCO Quality 2023: How Well Are Physicians Communicating With Women Who Have Breast Cancer?
ESMO 2023: Standardized Coaching Program May Improve Oral Treatment of Advanced Breast Cancer
ESMO 2023: KEYNOTE-522 Update on Use of Pembrolizumab in Triple-Negative Breast Cancer
ESMO 2023: Focus on Pathologic Complete Response in KEYNOTE-756 Breast Cancer Trial
ESMO 2023: Update From Phase III Trial of Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ESMO 2023: 5-Year Data From monarchE Support Abemaciclib + Endocrine Therapy
Hypofractionated Radiotherapy for Locally Advanced Breast Cancer
ESMO 2023: DESTINY-Breast04 Survival Update on T-DXd in HER2-Low Breast Cancer
ESMO 2023: Telephone-Based Weight Loss Program for Breast Cancer–Related Fatigue
ASTRO 2023: Can Neoadjuvant CRT Improve Outcomes in Locally Advanced Breast Cancer?
Can a Robotic Device Perform Effective Breast Examination? UK Researchers Say Yes
ASTRO 2023: Impact of BRCA1/2 Mutations on Outcomes Following Radiotherapy
ASTRO 2023: Is Preoperative Radiation Boost of Benefit in Treating Breast Cancer?
ASTRO 2023: Quality of Life and Radiation Fractionation Choices After Mastectomy
ASTRO 2023: Nipple-Preserving Radiotherapy After Surgery for Breast Cancer
Is Air Pollution Linked to Risk of Breast Cancer?
Breast Cancer Screening of Women in Their 40s: Clinical Implications of Canadian Study
Addressing the Health-Care Struggles of Transgender and Gender-Diverse Patients With Cancer
Is Radiation Necessary After Surgery for Patients With Low-Risk Breast Cancer?
Study to Explore Multimodality CNS Surveillance in Patients With HER2-Positive Breast Cancer
Final Overall Survival Findings From TROPiCS-02 With Sacituzumab Govitecan in Metastatic Breast Cancer
Does Stereotactic Radiosurgery for Breast Cancer Metastasis Induce Immune Responses?
Gene Enrichment Prognostic Clues for Breast Cancer in Adolescents and Young Adults
p-STAT3 Expression in Brain Metastases From Breast Cancer Subtypes: Impact on Clinical Outcomes
ASCOBT 2023: Patient-Related Outcomes in the Treatment of Breast Cancer–Related Lymphedema
ASCOBT 2023: Timing of Zoledronic Acid Use in Postmenopausal Patients Being Treated for Breast Cancer
Is Breast Cancer Overdiagnosed Among Older Women in the United States?
ASCOBT 2023: Impact of Muscle Mass and Strength on Chemotherapy-Induced Toxicity in Breast Cancer
Disparities in Early Breast Cancer Treatment in China Versus the United States
ASCOBT 2023: Subtype Classification Advances May Improve Personalized Treatment of Breast Cancer
Accelerated Biological Aging in Breast Cancer Survivors: Implications for Treatment Modalities
ASCOBT 2023: Topical Diclofenac and Hand-Foot Syndrome Linked to Capecitabine Treatment
Do Proton Pump Inhibitors Reduce the Efficacy of Palbociclib in Patients With Breast Cancer?
ASCOBT 2023: Robot-Assisted Breast-Conserving Surgery and Cosmetic Results
RAGE Inhibitors Under Study in Triple-Negative Breast Cancer
Can Nurse-Led Treatment Navigation Reduce Psychological Distress in Patients With Breast Cancer?
Secondary SOFT Analysis of Intrinsic Subtypes of Breast Cancer and Risk of Recurrence
Predictive Ability of Ancestry-Adjusted Polygenic Risk Scores for Breast Cancer
Can Donepezil Reduce Late Cancer-Related Cognitive Impairment in Breast Cancer Survivors?
Using Biomarkers to Predict Response to Immunotherapy in Breast Cancer: I-SPY2 Trial
Does Pairing Fulvestrant and Palbociclib Improve Clinical and Kinetic Outcomes in ESR1-Mutated Breast Cancer?
EMERALD Subgroup Analysis of Oral Elacestrant in Advanced Breast Cancer
Screening Women With Dense Breasts: Abbreviated Breast MRI Versus Digital Breast Tomosynthesis
Ovarian Suppression and Breast Cancer Recurrence and Survival
Repeat Biopsies and Likelihood of Identifying HER2-Low Triple-Negative Breast Cancer
Electronic Assessment of Quality of Life in Patients Being Treated for Metastatic Breast Cancer
ASCO 2023: Age-Specific Update From DESTINY Trials of T-DXd in Metastatic Breast Cancer
FDA Brief: Iopromide Injection Approved for Contrast-Enhanced Mammography
ACR and SBI Comment on Updated USPSTF Breast Cancer Screening Recommendations
ASCO 2023: Predicting Response to Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer
Harvard Researchers Identify Molecular Trigger Behind Certain Types of Breast Cancer
ASCO 2023: Novel Antibody-Drug Conjugate Shows Clinical Activity in Metastatic Breast Cancer
ASCO 2023: Path to Chemotherapy-Free Treatment of Early-Stage Breast Cancer Becomes Clearer for Some
ASCO 2023: SONIA Trial Analysis Offers Insight on Timing of CDK4/6 Inhibitor Therapy
ASCO 2023: Use of Abemaciclib Plus Endocrine Therapy by Age Subgroups With High-Risk, Early-Stage Breast Cancer
ASCO 2023: Palbociclib Maintenance in Second-Line Endocrine Therapy for Advanced Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.